• Skip to main content
  • Skip to header right navigation
  • Skip to site footer
PALB2 Interest Group

PALB2 Interest Group

  • Home
  • About the PALB2 gene
    • PALB2 mutation and cancer risks
    • A Study of Cancer Risks in PALB2 Mutation Carriers
    • Clinician Info
    • FAQS
  • Team
    • Our Team
    • Our Collaborators
  • Resources
  • Publications
  • Events
  • Contact Us

Exciting results from a study looking at PARP inhibitors in the treatment of PALB2 breast cancers

October 18, 2022

A group of researchers from the US has reported some exciting results using Talazoparib, a PARP inhibitor. They treated five PALB2 carriers with breast cancer and one carrier with pancreatic cancer, and all cancers responded to the drug. The numbers are very small and more studies need to be done but this is exciting early evidence that PARP inhibitors are effective against PALB2 cancers. The full study can be accessed here:

https://rdcu.be/cXNOl

Gruber, J.J., Afghahi, A., Timms, K. et al. A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes. Nat Cancer (2022). https://doi.org/10.1038/s43018-022-00439-1

Category: News
 
Previous Post: « 3rd UK PALB2 Information Session for gene carriers and their families: 5pm UK time, 6th Oct 2022
Next Post: 3rd PALB2 information evening 6th Oct 2022- recording now available »

Copyright © 2023 · PALB2 Interest Group · All Rights Reserved · Send comments to add-tr.palb2@nhs.net. Hosted by Clinical School Computing Service